Article
Abnormal activation of NF-κB and MAPK signaling pathways affect osimertinib resistance and influence the recruitment of myeloid-derived suppressor cells to shape the immunosuppressive tumor immune microenvironment.
Thoracic cancer - 1 Jul 2023
Wang Chao, Fei Kailun, Liu Lihui, Duan Jianchun, Wang Zhijie, Li Sini, Xu Jiachen, Zhang Xue, Tian Yanhua, Qu Yan, Bai Hua, Wang Jie
Abstract excerpt
BACKGROUND: Osimertinib is the first-line treatment for patients with epidermal growth factor receptor (EGFR) mutations, but the treatment options after drug resistance are limited. Previous studies have suggested that EGFR is in an immunosuppressive tumor immune microenvironment (TIME). However, the evolution of TIME after osimertinib resistance and whether this resistance can be overcome by targeting TIME needs...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.